Skip to main content

Articles

Leukemia, Oncology

Chemotherapy-Free Induction with Ibrutinib plus Rituximab Shows Unprecedented Efficacy in MCL

Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma

R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma

Novel Hypomethylating Agent Active in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS

Multiple Myeloma, Oncology

Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma

The Hematology Pipeline Features New Immune Therapies, and Targeted Agents

Health Plans Must Monitor the Oncology Pipeline to Apply Appropriate Coverage Criteria, Maintain Treatment Value

CAR T-Cell Therapy Succeeds in Aggressive Lymphoma

Practice Management

Induction Therapy plus Autologous Stem-Cell Transplantation Still Cost-Effective for Newly Diagnosed Multiple Myeloma

Page 97 of 244
Results 961 - 970 of 2436